Oric Pharmaceuticals (NASDAQ:ORIC – Free Report) had its price target boosted by Citigroup from $16.00 to $17.00 in a research report released on Tuesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.
ORIC has been the topic of several other reports. Wedbush cut their price objective on Oric Pharmaceuticals from $17.00 to $14.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research note on Thursday, October 15th. Stifel Nicolaus upped their target price on Oric Pharmaceuticals from $14.00 to $18.00 and gave the stock a “buy” rating in a research report on Monday, October 26th. Leerink Partners started coverage on Oric Pharmaceuticals in a research report on Monday, October 5th. They issued an “outperform” rating and a $26.00 target price for the company. Finally, Wall Street Zen upgraded Oric Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, July 25th. Thirteen investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $20.18.
Read Our Latest Stock Analysis on ORIC
Oric Pharmaceuticals Price Performance
Shares of ORIC stock opened at $7.70 on Tuesday. The company’s fifty day simple moving average is $11.17 and its 200-day simple moving average is $10.95. Oric Pharmaceuticals has a 52 week low of $7.23 and a 52 week high of $14.68.
Oric Pharmaceuticals (NASDAQ:ORIC – Get Free Report) last announced its quarterly earnings results on Monday, November 16th. The company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.05). As a group, research analysts forecast that Oric Pharmaceuticals will post -1.58 earnings per share for the current year.
Insider Activity
In other news, CFO Dominic Piscitelli sold 14,000 shares of the business’s stock in a transaction on Tuesday, October 20th. The shares were sold at an average price of $13.53, for a total transaction of $189,420.00. Following the transaction, the chief financial officer directly owned 69,828 shares of the company’s stock, valued at approximately $944,772.84. The trade was a 16.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 105,000 shares of company stock worth $1,432,952 in the last 90 days. Company insiders own 5.70% of the company’s stock.
Institutional Investors Weigh In On Oric Pharmaceuticals
A number of large investors have recently added to or reduced their stakes in ORIC. Algert Global LLC lifted its holdings in Oric Pharmaceuticals by 33.5% in the 3rd quarter. Algert Global LLC now owns 1,621,908 shares of the company’s stock worth $21,847,000 after buying an additional 406,615 shares in the last quarter. New York State Common Retirement Fund boosted its position in Oric Pharmaceuticals by 43.4% in the 3rd quarter. New York State Common Retirement Fund now owns 26,429 shares of the company’s stock valued at $356,000 after buying an additional 8,000 shares during the last quarter. Quarry LP boosted its position in Oric Pharmaceuticals by 23.9% in the 3rd quarter. Quarry LP now owns 20,848 shares of the company’s stock valued at $281,000 after buying an additional 4,018 shares during the last quarter. Bellevue Group AG acquired a new stake in shares of Oric Pharmaceuticals during the third quarter valued at about $75,000. Finally, Toronto Dominion Bank acquired a new stake in shares of Oric Pharmaceuticals during the third quarter valued at about $5,253,000. 95.05% of the stock is owned by institutional investors and hedge funds.
Latest Oric Pharmaceuticals News
These are some of the ORIC news items that stood out recently:
- Positive Sentiment: A separate report said ORIC shares rose following an analyst upgrade, suggesting the rating change provided a near-term catalyst. Shares Up Following Analyst Upgrade
- Neutral Sentiment: Analysts’ reported consensus price target is $21.33, well above the cited $7.70 share price, but a target is an estimate rather than a guarantee. Consensus Price Target
- Negative Sentiment: HC Wainwright cut its target from $27 to $20 while maintaining a “Buy” rating; Wells Fargo lowered its target from $25 to $23 but retained an “Overweight” rating. The reductions may temper optimism, despite both firms remaining bullish. HC Wainwright Rating Wells Fargo Rating
Oric Pharmaceuticals Company Profile
Oric Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its research centers on therapies intended to address treatment resistance and improve outcomes for people with tumors that have become difficult to treat. The company’s drug candidates have included ORIC-114, a targeted therapy designed to inhibit EGFR and HER2 alterations, and ORIC-944, which targets the PRC2 pathway and has been investigated for prostate cancer. These programs are investigational and are not approved medicines.
Further Reading
- Five stocks we like better than Oric Pharmaceuticals
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Oric Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oric Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
